Abingdon Health appoints non-executive chairman and directors

Peter Woodford, Chris Yates and Dr Rebecca Todd join the team

Diagnostics company, Abingdon Health, has announced the appointments of Peter Woodford as non-executive chairman and Chris Yates and Dr Rebecca Todd as non-executive directors.

Woodford has more than 40 years’ experience in the medical devices sector and currently holds board positions at a number of private healthcare companies. He is the chairman of Abingdon’s portfolio company, Molecular Vision; chairman of Applied Physiology Pty, a global company developing software for the critical care market; and a non-executive director of Lein Applied Diagnostics, a research company developing non-invasive ophthalmic diagnostics. He is also the founder and principal of Consult Iridium, a strategic business consultancy advising healthcare industry enterprises and investors. Prior to founding Consult Iridium, he held a number of senior corporate roles including senior vice president of Roche Diabetes Care.

Yates is currently chief financial officer of private equity-backed, Nexus Vehicle Rental. He co-founded Abingdon Health with Dr Chris Hand and Dr Brett Pollard in 2008 and prior to that was finance director of medical diagnostics group, Cozart, until its £65m sale to Concateno in 2007. Between 1999-2005 he worked in growth company corporate finance at Schroders, ING Barings and Piper Jaffray.

Dr Todd is a director on Imperial Innovations Group’s healthcare ventures and investment team, which is an investor in Abingdon. Prior to this she spent four years at Oxford Capital Partners, where she managed the healthcare investment portfolio. Her earlier career was as a marketing consultant, initially to major pharmaceutical companies and latterly to early-stage life science technology companies.

Chris Hand, Abingdon’s chief executive, said: “The appointments of Peter, Chris and Rebecca have significantly strengthened the board. This is another important step for Abingdon and their experience and contribution will be of significant value as we continue to progress our strategy of creating a commercially-focused medical diagnostics business.”

Companies